Cargando…
Evaluation of early innate and adaptive immune responses to the TB vaccine Mycobacterium bovis BCG and vaccine candidate BCGΔBCG1419c
The vaccine Mycobacterium bovis Bacillus Calmette-Guérin (BCG) elicits an immune response that is protective against certain forms of tuberculosis (TB); however, because BCG efficacy is limited it is important to identify alternative TB vaccine candidates. Recently, the BCG deletion mutant and vacci...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300728/ https://www.ncbi.nlm.nih.gov/pubmed/35858977 http://dx.doi.org/10.1038/s41598-022-14935-y |
_version_ | 1784751278808629248 |
---|---|
author | Gunasena, Manuja Shukla, Rajni Kant Yao, Naiquan Rosas Mejia, Oscar Powell, Michael D. Oestreich, Kenneth J. Aceves-Sánchez, Michel de Jesús Flores-Valdez, Mario Alberto Liyanage, Namal P. M. Robinson, Richard T. |
author_facet | Gunasena, Manuja Shukla, Rajni Kant Yao, Naiquan Rosas Mejia, Oscar Powell, Michael D. Oestreich, Kenneth J. Aceves-Sánchez, Michel de Jesús Flores-Valdez, Mario Alberto Liyanage, Namal P. M. Robinson, Richard T. |
author_sort | Gunasena, Manuja |
collection | PubMed |
description | The vaccine Mycobacterium bovis Bacillus Calmette-Guérin (BCG) elicits an immune response that is protective against certain forms of tuberculosis (TB); however, because BCG efficacy is limited it is important to identify alternative TB vaccine candidates. Recently, the BCG deletion mutant and vaccine candidate BCGΔBCG1419c was demonstrated to survive longer in intravenously infected BALB/c mice due to enhanced biofilm formation, and better protected both BALB/c and C57BL/6 mice against TB-induced lung pathology during chronic stages of infection, relative to BCG controls. BCGΔBCG1419c-elicited protection also associated with lower levels of proinflammatory cytokines (i.e. IL6, TNFα) at the site of infection in C57BL/6 mice. Given the distinct immune profiles of BCG- and BCGΔBCG1419c-immunized mice during chronic TB, we set out to determine if there are early immunological events which distinguish these two groups, using multi-dimensional flow cytometric analysis of the lungs and other tissues soon after immunization. Our results demonstrate a number of innate and adaptive response differences between BCG- and BCGΔBCG1419c-immunized mice which are consistent with the latter being longer lasting and potentially less inflammatory, including lower frequencies of exhausted CD4(+) T helper (T(H)) cells and higher frequencies of IL10-producing T cells, respectively. These studies suggest the use of BCGΔBCG1419c may be advantageous as an alternative TB vaccine candidate. |
format | Online Article Text |
id | pubmed-9300728 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-93007282022-07-22 Evaluation of early innate and adaptive immune responses to the TB vaccine Mycobacterium bovis BCG and vaccine candidate BCGΔBCG1419c Gunasena, Manuja Shukla, Rajni Kant Yao, Naiquan Rosas Mejia, Oscar Powell, Michael D. Oestreich, Kenneth J. Aceves-Sánchez, Michel de Jesús Flores-Valdez, Mario Alberto Liyanage, Namal P. M. Robinson, Richard T. Sci Rep Article The vaccine Mycobacterium bovis Bacillus Calmette-Guérin (BCG) elicits an immune response that is protective against certain forms of tuberculosis (TB); however, because BCG efficacy is limited it is important to identify alternative TB vaccine candidates. Recently, the BCG deletion mutant and vaccine candidate BCGΔBCG1419c was demonstrated to survive longer in intravenously infected BALB/c mice due to enhanced biofilm formation, and better protected both BALB/c and C57BL/6 mice against TB-induced lung pathology during chronic stages of infection, relative to BCG controls. BCGΔBCG1419c-elicited protection also associated with lower levels of proinflammatory cytokines (i.e. IL6, TNFα) at the site of infection in C57BL/6 mice. Given the distinct immune profiles of BCG- and BCGΔBCG1419c-immunized mice during chronic TB, we set out to determine if there are early immunological events which distinguish these two groups, using multi-dimensional flow cytometric analysis of the lungs and other tissues soon after immunization. Our results demonstrate a number of innate and adaptive response differences between BCG- and BCGΔBCG1419c-immunized mice which are consistent with the latter being longer lasting and potentially less inflammatory, including lower frequencies of exhausted CD4(+) T helper (T(H)) cells and higher frequencies of IL10-producing T cells, respectively. These studies suggest the use of BCGΔBCG1419c may be advantageous as an alternative TB vaccine candidate. Nature Publishing Group UK 2022-07-20 /pmc/articles/PMC9300728/ /pubmed/35858977 http://dx.doi.org/10.1038/s41598-022-14935-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Gunasena, Manuja Shukla, Rajni Kant Yao, Naiquan Rosas Mejia, Oscar Powell, Michael D. Oestreich, Kenneth J. Aceves-Sánchez, Michel de Jesús Flores-Valdez, Mario Alberto Liyanage, Namal P. M. Robinson, Richard T. Evaluation of early innate and adaptive immune responses to the TB vaccine Mycobacterium bovis BCG and vaccine candidate BCGΔBCG1419c |
title | Evaluation of early innate and adaptive immune responses to the TB vaccine Mycobacterium bovis BCG and vaccine candidate BCGΔBCG1419c |
title_full | Evaluation of early innate and adaptive immune responses to the TB vaccine Mycobacterium bovis BCG and vaccine candidate BCGΔBCG1419c |
title_fullStr | Evaluation of early innate and adaptive immune responses to the TB vaccine Mycobacterium bovis BCG and vaccine candidate BCGΔBCG1419c |
title_full_unstemmed | Evaluation of early innate and adaptive immune responses to the TB vaccine Mycobacterium bovis BCG and vaccine candidate BCGΔBCG1419c |
title_short | Evaluation of early innate and adaptive immune responses to the TB vaccine Mycobacterium bovis BCG and vaccine candidate BCGΔBCG1419c |
title_sort | evaluation of early innate and adaptive immune responses to the tb vaccine mycobacterium bovis bcg and vaccine candidate bcgδbcg1419c |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300728/ https://www.ncbi.nlm.nih.gov/pubmed/35858977 http://dx.doi.org/10.1038/s41598-022-14935-y |
work_keys_str_mv | AT gunasenamanuja evaluationofearlyinnateandadaptiveimmuneresponsestothetbvaccinemycobacteriumbovisbcgandvaccinecandidatebcgdbcg1419c AT shuklarajnikant evaluationofearlyinnateandadaptiveimmuneresponsestothetbvaccinemycobacteriumbovisbcgandvaccinecandidatebcgdbcg1419c AT yaonaiquan evaluationofearlyinnateandadaptiveimmuneresponsestothetbvaccinemycobacteriumbovisbcgandvaccinecandidatebcgdbcg1419c AT rosasmejiaoscar evaluationofearlyinnateandadaptiveimmuneresponsestothetbvaccinemycobacteriumbovisbcgandvaccinecandidatebcgdbcg1419c AT powellmichaeld evaluationofearlyinnateandadaptiveimmuneresponsestothetbvaccinemycobacteriumbovisbcgandvaccinecandidatebcgdbcg1419c AT oestreichkennethj evaluationofearlyinnateandadaptiveimmuneresponsestothetbvaccinemycobacteriumbovisbcgandvaccinecandidatebcgdbcg1419c AT acevessanchezmicheldejesus evaluationofearlyinnateandadaptiveimmuneresponsestothetbvaccinemycobacteriumbovisbcgandvaccinecandidatebcgdbcg1419c AT floresvaldezmarioalberto evaluationofearlyinnateandadaptiveimmuneresponsestothetbvaccinemycobacteriumbovisbcgandvaccinecandidatebcgdbcg1419c AT liyanagenamalpm evaluationofearlyinnateandadaptiveimmuneresponsestothetbvaccinemycobacteriumbovisbcgandvaccinecandidatebcgdbcg1419c AT robinsonrichardt evaluationofearlyinnateandadaptiveimmuneresponsestothetbvaccinemycobacteriumbovisbcgandvaccinecandidatebcgdbcg1419c |